APA (7th ed.) Citation

HF, T., LS, S., E, R., BK, A., JH, K., J, W., . . . L, Q. (2025). Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease. Human vaccines & immunotherapeutics, 21(1), 2576981. https://doi.org/10.1080/21645515.2025.2576981

Chicago Style (17th ed.) Citation

HF, Tseng, et al. "Effectiveness and Safety of the Recombinant Zoster Vaccine in Adults Aged ≥50 years with Inflammatory Bowel Disease." Human Vaccines & Immunotherapeutics 21, no. 1 (2025): 2576981. https://doi.org/10.1080/21645515.2025.2576981.

MLA (9th ed.) Citation

HF, Tseng, et al. "Effectiveness and Safety of the Recombinant Zoster Vaccine in Adults Aged ≥50 years with Inflammatory Bowel Disease." Human Vaccines & Immunotherapeutics, vol. 21, no. 1, 2025, p. 2576981, https://doi.org/10.1080/21645515.2025.2576981.